Evaluation of the efficacy of the accelerated radiotherapy in squamous cell carcinoma of head and neck

• HNSCC is the sixth most common cancer worldwide, with 890.000 new cases and 450.000 deaths in 2018.
• The incidence of HNSCC continues to rise and is anticipated to increase by 30% (that is, 1.08 million new cases annually) by 2030.
• Squamous cell carcinoma constitutes 90% of all head and neck cancers and it predominates in males.
• Risk factors such as cigarette consumption and alcohol consumption, are well established.
• Treatment decisions are guided by clinic-pathologic factors such as age and stage.
• Treatment of the majority of patients with HNSCC requires multimodality approaches.
• Radiotherapy or surgery alone can be considered as the standard treatment modality for patients having early head and neck squamous cell carcinoma.
• When conventionally fractionated radiotherapy is used, long-term tumor control can be achieved in less than 30% of patients with advanced head and neck carcinomas.

Inclusion Criteria:

• Patients of (18 up to 75 years of age)
• Performance status of 0-2 according to ECOG scale.
• Patients with no prior chemotherapy, radiotherapy or surgery except for biopsy.

Exclusion Criteria:

• Patients with previous irradiation to head and neck.
• Pregnant or lactating women.
• Patients with impaired heart or lung diseases.

-Patients of (18 up to 75 years of age)